PTGS2 and nonpapillary renal cell carcinoma: PTGS2 was reported to distinguish ccRCC from the remaining RCTs subtypes with 46% sensitivity and 91% specificity [13], and we demonstrated that OXR1 and MST1R reached a superior performance in all validity estimates.